



NDA 021928/S-051

APPROVAL LETTER

Pf Prism C.V.
Attention: Elizabeth Mauro
Director, Pfizer Global Regulatory Sciences
66 Hudson Boulevard East
New York, NY 10001-2192

Dear Elizabeth Mauro:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 25, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for CHANTIX (varenicline) tablets.

We acknowledge receipt of your amendment dated February 24, 2025, which constituted a complete response to our January 24, 2025, action letter.

This Prior Approval supplemental new drug application provides for the following:

1. Addition of Pfizer Ireland Pharmaceuticals located in Newbridge Ireland (FEI: 3006785053), as ^{(b) (4)}

2. ^{(b) (4)}

3. ^{(b) (4)}

4. ^{(b) (4)}

5. ^{(b) (4)}

6. ^{(b) (4)}

7. Re-launching in bottles and wallet cards with minor change to the wallet presentation, where the outer carton will no longer be used, and the product will be supplied using the wallet card only.
8. USPI updates include:

- Change in Pfizer logo and headquarters address.
 - Update to Section 16 HOW SUPPLIED/STORAGE AND HANDLING with a change in NDC numbers and removal of folding carton
9. Container and carton label artwork updates include:
- Removal of the folding carton
 - Removal of (b) (4)
 - Change in Pfizer logo.
 - Update to the signature line block – zip code.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information, and Medication Guide) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are

printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 021928/S-051.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Teicher Agosto, Regulatory Business Process Manager, at (240) 402 - 3777.

Sincerely,

{See appended electronic signature page}

Vilayat Sayeed, Ph. D
Director, Division of Product Quality Assessment II
Office of Product Quality Assessment I
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling
Carton and Container Labeling



Vilayat
Sayeed

Digitally signed by Vilayat Sayeed

Date: 6/24/2025 03:14:13PM

GUID: 508da70600028a7aad41a1cc455d8261